^
BIOMARKER:

MET amplification

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Phase 1/2
Regeneron Pharmaceuticals
Recruiting
Last update posted :
09/23/2022
Initiation :
01/07/2020
Primary completion :
10/20/2024
Completion :
10/20/2024
MET
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation
|
REGN5093 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/19/2022
Initiation :
01/30/2019
Primary completion :
01/31/2023
Completion :
01/31/2023
BRAF • KRAS • MET • MSI
|
MET amplification • KRAS wild-type • NRAS wild-type
|
Orpathys (savolitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/13/2022
Initiation :
03/01/2018
Primary completion :
05/09/2022
Completion :
09/09/2023
EGFR • PD-L1 • ALK • RET • ROS1
|
EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • RET rearrangement • EGFR G719X • EGFR negative • MET-H
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/09/2022
Initiation :
05/22/2020
Primary completion :
05/01/2023
Completion :
05/01/2023
PD-L1 • ALK • RET • ROS1
|
EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • RET rearrangement • EGFR G719X • EGFR negative • MET-H
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • CMAB 819 (nivolumab biosimilar) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)
Phase 2
AstraZeneca
Active, not recruiting
Last update posted :
09/08/2022
Initiation :
09/28/2020
Primary completion :
12/21/2022
Completion :
12/20/2024
EGFR • MET
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification
|
Tagrisso (osimertinib) • Orpathys (savolitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
AstraZeneca
Recruiting
Last update posted :
09/07/2022
Initiation :
01/09/2019
Primary completion :
05/27/2024
Completion :
02/28/2025
EGFR • MET
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression
|
Tagrisso (osimertinib) • Orpathys (savolitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
08/25/2022
Initiation :
12/02/2021
Primary completion :
11/01/2023
Completion :
11/01/2023
HER-2
|
MET amplification • EGFR amplification
|
Rybrevant (amivantamab-vmjw) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Merck KGaA, Darmstadt, Germany
Completed
Last update posted :
08/24/2022
Initiation :
12/23/2013
Primary completion :
12/12/2017
Completion :
10/14/2021
MET
|
EGFR mutation • MET amplification • MET overexpression • EGFR T790M negative
|
cisplatin • gefitinib • carboplatin • pemetrexed • Tepmetko (tepotinib)
Phase 1
EMD Serono
Completed
Last update posted :
08/24/2022
Initiation :
11/30/2009
Primary completion :
10/31/2015
Completion :
10/31/2015
MET
|
MET amplification • MET mutation • MET expression
|
Tepmetko (tepotinib)
Phase 2
AbbVie
Not yet recruiting
Last update posted :
08/24/2022
Initiation :
11/16/2022
Primary completion :
11/15/2025
Completion :
11/15/2026
MET
|
MET amplification
|
telisotuzumab vedotin (ABBV-399)
Phase 1
Janssen Research & Development, LLC
Recruiting
Last update posted :
08/18/2022
Initiation :
05/24/2016
Primary completion :
01/04/2024
Completion :
01/26/2024
ALK • MET
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • EGFR exon 20 mutation • EGFR positive • MET expression
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
08/09/2022
Initiation :
10/15/2018
Primary completion :
12/31/2023
Completion :
12/31/2023
MET
|
MET amplification • MET mutation • MET fusion • HGF amplification
|
Orpathys (savolitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
EMD Serono Research & Development Institute, Inc.
Recruiting
Last update posted :
08/04/2022
Initiation :
09/19/2019
Primary completion :
11/30/2022
Completion :
03/30/2023
EGFR • MET
|
EGFR mutation • MET amplification
|
Tagrisso (osimertinib) • Tepmetko (tepotinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Byondis B.V.
Recruiting
Last update posted :
08/03/2022
Initiation :
03/21/2022
Primary completion :
01/01/2025
Completion :
03/01/2025
MET
|
MET amplification • MET exon 14 mutation • MET mutation • MET positive
|
BYON3521 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
07/28/2022
Initiation :
04/29/2013
Primary completion :
09/12/2019
Completion :
03/14/2023
MET
|
MET amplification
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase 1/2
Apollomics Inc.
Recruiting
Last update posted :
07/27/2022
Initiation :
09/27/2017
Primary completion :
03/30/2026
Completion :
11/30/2026
EGFR • PTPRZ1
|
MET amplification • EGFR wild-type • MET exon 14 mutation • MET fusion • MET-H
|
bozitinib (APL-101) • CBT101 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 3
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
07/27/2022
Initiation :
09/22/2021
Primary completion :
05/11/2022
Completion :
12/30/2022
EGFR • MET
|
EGFR mutation • MET amplification • EGFR T790M negative
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Tabrecta (capmatinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1b/2
Hallym University Medical Center
Recruiting
Last update posted :
07/04/2022
Initiation :
03/01/2022
Primary completion :
06/30/2026
Completion :
06/30/2026
MET
|
MET amplification • MET exon 14 mutation
|
paclitaxel • Tepmetko (tepotinib)
Phase 1
Instituto Oncológico Dr Rosell
Recruiting
Last update posted :
07/04/2022
Initiation :
02/11/2022
Primary completion :
04/01/2026
Completion :
06/01/2026
EGFR • ALK • MET • ROS1 • HAVCR2 • NTRK
|
EGFR mutation • EGFR T790M • MET amplification • EGFR C797S • EGFR exon 18 mutation
|
Tagrisso (osimertinib) • repotrectinib (TPX-0005) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Criterium, Inc.
Recruiting
Last update posted :
07/01/2022
Initiation :
05/25/2022
Primary completion :
06/30/2025
Completion :
07/31/2027
EGFR • ALK • MET
|
MET amplification • MET exon 14 mutation • MET fusion
|
Tepmetko (tepotinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
M.D. Anderson Cancer Center
Completed
Last update posted :
06/30/2022
Initiation :
03/01/2013
Primary completion :
03/01/2019
Completion :
03/01/2019
BRAF • ALK • MET • CDKN2A • DDR2 • CTGF
|
BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification
|
Xalkori (crizotinib) • dasatinib
Phase 1
Fate Therapeutics
Recruiting
Last update posted :
06/22/2022
Initiation :
05/31/2022
Primary completion :
06/01/2024
Completion :
04/01/2027
EGFR • HER-2 • KRAS • NRAS • MET
|
PD-L1 expression • EGFR mutation • MET amplification • HER-2 expression • MET exon 14 mutation • KRAS wild-type • RAS wild-type • NRAS wild-type
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • Bavencio (avelumab) • cyclophosphamide • Rybrevant (amivantamab-vmjw) • fludarabine IV • FT536 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1a
Symphogen A/S
Completed
Last update posted :
06/22/2022
Initiation :
03/01/2016
Primary completion :
12/01/2020
Completion :
12/01/2020
EGFR • KRAS • MET
|
MET amplification • KRAS wild-type • RAS wild-type
|
Sym015 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Janssen Research & Development, LLC
Recruiting
Last update posted :
06/21/2022
Initiation :
05/24/2016
Primary completion :
01/04/2024
Completion :
01/04/2024
ALK • MET
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • EGFR exon 20 mutation • EGFR positive • MET expression
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
Phase 1
Janssen Research & Development, LLC
Recruiting
Last update posted :
06/21/2022
Initiation :
05/24/2016
Primary completion :
01/04/2024
Completion :
01/04/2024
ALK • MET
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • EGFR exon 20 mutation • EGFR positive • MET expression
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
Phase 1
Janssen Research & Development, LLC
Recruiting
Last update posted :
06/21/2022
Initiation :
05/24/2016
Primary completion :
01/04/2024
Completion :
01/04/2024
ALK • MET
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • EGFR exon 20 mutation • EGFR positive • MET expression
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
Phase 1
Janssen Research & Development, LLC
Recruiting
Last update posted :
06/21/2022
Initiation :
05/24/2016
Primary completion :
01/04/2024
Completion :
01/04/2024
ALK • MET
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • EGFR exon 20 mutation • EGFR positive • MET expression
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
Phase 2
Samsung Medical Center
Completed
Last update posted :
06/15/2022
Initiation :
02/10/2016
Primary completion :
12/30/2020
Completion :
08/27/2021
MET
|
MET amplification
|
Orpathys (savolitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Samsung Medical Center
Completed
Last update posted :
06/15/2022
Initiation :
04/30/2015
Primary completion :
06/30/2020
Completion :
09/20/2020
MET
|
MET amplification
|
docetaxel • Orpathys (savolitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
06/03/2022
Initiation :
07/30/2022
Primary completion :
09/21/2023
Completion :
09/04/2028
MET
|
MET amplification • MET exon 14 mutation • MET mutation
|
Tabrecta (capmatinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/25/2022
Initiation :
05/08/2017
Primary completion :
06/30/2021
Completion :
07/01/2022
MET • RET • AXL
|
MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Assistance Publique - Hôpitaux de Paris
Recruiting
Last update posted :
05/17/2022
Initiation :
03/22/2022
Primary completion :
04/01/2023
Completion :
10/01/2025
HER-2 • MET
|
HER-2 positive • MET amplification
|
Tabrecta (capmatinib) • spartalizumab (PDR001) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
University Health Network, Toronto
Completed
Last update posted :
05/17/2022
Initiation :
03/01/2018
Primary completion :
08/20/2020
Completion :
02/18/2022
EGFR • MET
|
MET amplification • MET exon 14 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
AstraZeneca
Not yet recruiting
Last update posted :
05/16/2022
Initiation :
06/30/2022
Primary completion :
10/31/2023
Completion :
05/31/2024
EGFR • MET
|
MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation
|
Imfinzi (durvalumab) • Orpathys (savolitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Abion Inc
Recruiting
Last update posted :
05/05/2022
Initiation :
08/01/2019
Primary completion :
12/31/2023
Completion :
12/31/2023
MET
|
MET amplification • MET exon 14 mutation • MET overexpression
|
ABN401 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Shanghai EpimAb Biotherapeutics Co., Ltd.
Recruiting
Last update posted :
04/19/2022
Initiation :
10/21/2021
Primary completion :
08/04/2024
Completion :
08/31/2024
EGFR • MET
|
EGFR mutation • MET amplification • EGFR expression • EGFR overexpression • MET overexpression
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • bafisontamab (EMB-01)
Phase 1/2
Turning Point Therapeutics, Inc.
Recruiting
Last update posted :
04/08/2022
Initiation :
08/20/2019
Primary completion :
11/01/2022
Completion :
11/01/2023
MET
|
MET amplification • MET exon 14 mutation • MET mutation
|
elzovantinib (TPX-0022) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Not yet recruiting
Last update posted :
03/31/2022
Initiation :
05/01/2022
Primary completion :
05/01/2024
Completion :
05/01/2025
MET
|
MET amplification
|
ASKC202 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
RemeGen Co., Ltd.
Active, not recruiting
Last update posted :
01/28/2022
Initiation :
09/26/2018
Primary completion :
08/19/2021
Completion :
05/30/2022
HER-2 • MET
|
EGFR mutation • HER-2 overexpression • HER-2 mutation • EGFR T790M • MET amplification • MET mutation • HER-2 exon 20 mutation
|
Aidixi (disitamab vedotin) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Amgen
Completed
Last update posted :
12/28/2021
Initiation :
04/15/2014
Primary completion :
11/05/2015
Completion :
12/07/2018
MET
|
MET amplification
|
AMG 337
Phase 2
Guangdong Association of Clinical Trials
Not yet recruiting
Last update posted :
12/20/2021
Initiation :
12/01/2021
Primary completion :
12/01/2023
Completion :
08/01/2026
MET
|
EGFR mutation • MET amplification • MET overexpression • MET expression • MET-H
|
Tagrisso (osimertinib) • Orpathys (savolitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)